About The Study:
During the Covid-19 pandemic, we saw that the omicron variant was the most contagious, and was one of the dominant strains of the virus present in the United States. More people were seen getting hospitalized due to the omicron variant being so infectious. The current vaccines available are not as effective at preventing infection to the newer variants, specifically the omicron one. We are hoping to find a booster vaccine that specifically protects against the omicron variant. Pfizer has made a booster vaccine and it is currently in the 2nd phase of trials. The purpose of the vaccine is to test the tolerability of the Omicron variant, specifically the BA.4 and BA.5 strain. Rochester Clinical Research is looking for healthy individuals over the age of 12, who have previously received 3 doses of covid vaccines from Pfizer, to participate in the study. The trial is approximately 6 months long and includes 5 visits to our office to be seen. Compensation is available for your time and travel if you participate in the study.
- 18 Years or older
- Willing and able to sign informed consent
- Aren't pregnant or breastfeeding
- Received 3 doses of Pfizer Covid-19 vaccines prior
- *Please note, that other conditions may apply